肿瘤标志物AFP、CEA、SF及β2-MG检测对冠心病和高血压病的诊治及预后判断价值

 目的 探讨肿瘤标志物甲胎蛋白(Alpha fetoprotein,AFP)、癌胚抗原(Carcinoembryonic antigen,CEA)、铁蛋白(Serum ferritin,SF)及β₂-微球蛋白(β₂-microglobulin,β₂-MG)检测对于冠心病和高血压病患者诊治及预后判断的价值。方法 选择2017-02至2019-03就诊的部队官兵中冠心病患者40例(冠心病组)、高血压患者40例(高血压组)、冠心病合并高血压患者40例(冠心病合并高血压组)为研究对象,另选择同期在我院接受健康体检的健康官兵40例为对照组。采集4组受检者空腹静脉血,检测并对比各组间血清AFP、CEA、SF及β₂-MG水平差异,记录冠心病组、高血压组和冠心病合并高血压组血清SF、β₂-MG阳性检出率。结果 高血压组、冠心病组、冠心病合并高血压组AFP、CEA水平与对照组相比,差异无统计学意义;高血压组中β₂-MG为(3.60±1.83)ng/mL、SF为(202.96±99.06)ng/ml,冠心病组中β₂-MG为(3.41±1.31)ng/ml、SF为(200.84±103.29)ng/ml,冠心病合并高血压组中β₂-MG为(3.63±1.82)ng/ml、SF为(207.43±104.89)ng/ml,对照组中β₂-MG为(2.16±0.51)ng/ml、SF为(114.66±74.31)ng/ml,差异有统计学意义(P＜0.05);高血压、冠心病、冠心病合并高血压三组患者的血清β₂-MG、SF检测数值、阳性检出率比较,差异无统计学意义。结论 β₂-MG和SF参与了冠心病合并高血压、高血压、冠心病的病理生理过程,可将β₂-MG和SF作为临床诊治及判断预后及疗效的参考指标。

Changes and clinical significance of serum AFP,CEA, SF, β2-MG in patients with coronary heart disease and hypertension

Objective To investigate the changes and clinical significance of serum levels of alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), serum ferritin (SF) and β₂-microglobulin (β₂-MG) in patients with coronary heart disease (CHD) and hypertension.Methods From among the military outpatients who had visited Beijing Municipal Corps Hospital of Chinese People’s Armed Police Force between February 2017 and March 2019, 40 CHD patients (CHD group), 40 with hypertension (HTN group), and 40 with both CHD and hypertension (CHD and HTN group) were selected as the subjects, while another 40 healthy people served as the control group. The fasting venous blood of the four groups was tested. The levels of serum AFP, CEA, SF and β₂-MG in the four groups were detected and compared. The positive detection rates of serum SF and β₂-MG in the CHD group, HTN group and CHD and HTN group were recorded.Results There was no statistically significant difference in levels of AFP or CEA between the three groups and the control group (P>0.05). However, there was statistically significant difference in levels of β₂-MG and SF between the HTN group (3.60±1.83)ng/mL, (202.96±99.06)ng/mL], CHD group (3.41±1.31)ng/mL, (200.84±103.29)ng/mL], CHD and HTN group (3.63±1.82)ng/mL, (207.43±104.89)ng/mL]and the control group (2.16±0.51)ng/mL, (114.66±74.31)ng/mL] (P<0.05). There was no statistically significant difference in the positive detection rate of serum β₂-MG or SF between the HTN group, CHD group and CHD and HTN group(P>0.05).Conclusions The levels of CEA and AFP remain unchanged in patients with HTN, CHD and CHD and HTN. β₂-MG and SF participate in the physiological and pathological processes of HTN, CHD and CHD and HTN so that β₂-MG and SF can be used as indexes for clinical diagnosis of prognosis and efficacy.